Protalix Biotherapeutics, Inc. (PLX)
2.095
+0.02
(+1.21%)
USD |
NYAM |
Jan 12, 16:00
2.095
0.00 (0.00%)
After-Hours: 20:00
Protalix Biotherapeutics Research and Development Expense (Quarterly): 4.467M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| OraSure Technologies, Inc. | 9.592M |
| PAVmed, Inc. | 1.088M |
| Denali Therapeutics, Inc. | 101.95M |
| AIM ImmunoTech, Inc. | 0.525M |
| Armata Pharmaceuticals, Inc. | 5.824M |